U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.
Michelle Priest, Beau Kilmer, Ben Senator, C. Setodji
Rand health quarterly June 1, 2026 DOI: 10.7249/rhq-13-03-02 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Survey Peer reviewed |
|---|---|
| Population | U.S. adults |
| Topics | Microdosing |
| Key findings | Microdosing psilocybin, LSD, and MDMA is a prevalent practice among users of psychedelic substances, and these data can inform policy discussions about alternatives to prohibition. |
Abstract
An increasing number of U.S. states are implementing or considering alternative policies to the prohibition of some psychedelic substances for nonclinical purposes. The authors present new data and analysis to inform these discussions with survey results on the use of 11 psychedelic substances and detailed information about the prevalence of microdosing (i.e., taking a fraction of a full dose, often on a schedule) for psilocybin, LSD, and MDMA.